Psych MEQs / SAQs · Addiction psychiatry
Alcohol use disorder — detox, Wernicke, and relapse prevention (MEQ)
FRANZCP-style MEQ on AUD nosology, CIWA-Ar, benzodiazepine detox, Caine/Wernicke thiamine, naltrexone/acamprosate/disulfiram, psychosocial package.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Nosology. Seven DSM-5-TR criteria in twelve months = severe AUD (mild 2–3, moderate 4–5, severe ≥6). ICD-11 would likely frame alcohol dependence if impaired control, primacy of use, and persistence despite harm (with physiological features) are present — do not mix criterion counts with ICD labels carelessly.[6]
(ii) Assessment. ABCDE, glucose, trauma from fall, full alcohol/substance history (last drink time critical), MSE, suicide/violence/vulnerability risk, capacity regarding self-discharge, collateral. Score CIWA-Ar (ten items, max 67) to guide symptom-triggered benzodiazepines if assessable. Screen mood/psychosis/other substances (dual diagnosis). Labs: FBC, U and E, Mg/phosphate, LFTs, coags; imaging if head injury concern.[1][5][6]
(iii) Acute management. Admit — high risk (withdrawal already, fall, Wernicke features, AMA threat). Benzodiazepines first-line (e.g. diazepam or lorazepam 1–2 mg titrated if liver concern) symptom-triggered per CIWA-Ar protocol. Wernicke: Caine criteria met (malnutrition + oculomotor + cerebellar — any two suffice); give high-dose parenteral thiamine urgently (EFNS/RCP-style teaching often 500 mg IV TDS for days then step-down — follow local protocol); do not rely on oral thiamine alone; cover thiamine when giving glucose.[2][4][5] Supportive care, electrolytes, seizure precautions, continuous monitoring; escalate if evolving DT.
(iv) Relapse prevention (after stabilisation). Offer naltrexone 50 mg oral daily if opioid-free and LFTs acceptable; or acamprosate 666 mg TDS after detox if renal function allows; or supervised disulfiram 200–250 mg daily only with consent, education, and suitable candidate. State contraindications (naltrexone/opioids; acamprosate/severe renal failure; disulfiram/cardiac risk, unsupervised drinking).[3][7][8]
(v) Psychosocial and disposition. MET/CBT/mutual aid, social work for housing, safety planning for AMA risk, dual diagnosis follow-up, early outpatient addiction review, consider residential if community supports fail. Document capacity and least-restrictive options under jurisdiction-specific law without inventing foreign section numbers.[3][6]
Common errors
- Waiting for the full Wernicke triad
- Oral thiamine only for nystagmus + ataxia + malnutrition
- No named CIWA-Ar or benzodiazepine plan
- Starting naltrexone without opioid check
- Ignoring capacity/AMA and suicide risk
References
- [1]Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict, 1989.PMID 2597811
- [2]Caine D, Halliday GM, Kril JJ, et al. Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. J Neurol Neurosurg Psychiatry, 1997.PMID 9010400
- [3]Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry, 2018.PMID 29301420
- [4]Galvin R, Bråthen G, Ivashynka A, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol, 2010.PMID 20642790
- [5]Mayo-Smith MF Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. JAMA, 1997.PMID 9214531
- [6]Connor JP, Haber PS, Hall WD Alcohol use disorders. Lancet, 2016.PMID 26343838
- [7]Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA, 2014.PMID 24825644
- [8]Fuller RK, Gordis E Does disulfiram have a role in alcoholism treatment today? Addiction, 2004.PMID 14678055